Hereditary nonpolyposis colorectal cancer secondary prevention
|
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
|
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hereditary nonpolyposis colorectal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention |
|
FDA on Hereditary nonpolyposis colorectal cancer secondary prevention |
|
CDC on Hereditary nonpolyposis colorectal cancer secondary prevention |
|
Hereditary nonpolyposis colorectal cancer secondary prevention in the news |
|
Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention |
|
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
|
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.[1]
Secondary prevention
Recent studies demonstrate a reduced incidence in HNPCC patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA).
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:[1]
- Colonoscopy between 25-35 years, every 2 years.
- Pelvic exam, transvaginal ultrasound and CA-125 between 25-35 years, every year.
- Endometrial biopsy, in relation to clinical symptoms.
- Urine cytology (families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis, between 25-35 years every year)